medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/ms2026-278medsovet-10414Research ArticleРЕВМАТОЛОГИЯRHEUMATOLOGYКлинико-патогенетическое значение моноцитарного хемотаксического протеина-1 при ревматоидном артрите: обзор литературыClinical and pathogenetic significance of monocyte chemotactic protein-1 in rheumatoid arthritis: A literature reviewhttps://orcid.org/0000-0002-0965-6060СивордоваЛ. Е.SivordovaL. E.

Сивордова Лариса Евгеньевна - к.м.н., ведущий научный сотрудник лаборатории методов лечения и профилактики заболеваний суставов.

400138, Волгоград, ул. имени Землячки, д. 76, корп. 2

Larissa E. Sivordova - Cand. Sci. (Med.), Leading Researcher of the Laboratory of Methods for the Treatment and Prevention of Joint Diseases

76, Bldg. 2, Zemlyachka St., Volgograd, 400138

seeword@mail.ruhttps://orcid.org/0000-0002-8799-2991ПапичевЕ. В.PapichevE. V.

Папичев Евгений Васильевич - научный сотрудник лаборатории методов лечения и профилактики заболеваний суставов.

400138, Волгоград, ул. имени Землячки, д. 76, корп. 2

Eugene V. Papichev - Researcher of the Laboratory of Methods for the Treatment and Prevention of Joint Diseases.

76, Bldg. 2, Zemlyachka St., Volgograd, 400138

e_papichev@mail.ruhttps://orcid.org/0000-0002-3022-4166ПоляковаЮ. В.PolyakovaYu. V.

Полякова Юлия Васильевна - к.м.н., научный сотрудник лаборатории методов лечения и профилактики заболеваний суставов.

400138, Волгоград, ул. имени Землячки, д. 76, корп. 2

Yuliya V. Polyakova - Cand. Sci. (Med.), Researcher of the Laboratory of Methods for the Treatment and Prevention of Joint Diseases.

76, Bldg. 2, Zemlyachka St., Volgograd, 400138

jpolyakova@yandex.ruhttps://orcid.org/0000-0001-8010-6777АхвердянЮ. Р.AkhverdyanYu. R.

Ахвердян Юрий Рубенович - к.м.н., старший научный сотрудник лаборатории методов лечения и профилактики заболеваний суставов.

400138, Волгоград, ул. имени Землячки, д. 76, корп. 2

Yuri R. Akhverdyan - Cand. Sci. (Med.), Senior Researcher of the Laboratory of Methods for the Treatment and Prevention of Joint Diseases.

76, Bldg. 2, Zemlyachka St., Volgograd, 400138

doctor_2001@mail.ruhttps://orcid.org/0000-0002-8124-4239АлександроваН. А.AleksandrovaN. A.

Александрова Нинель Владимировна - к.м.н., старший научный сотрудник лаборатории функциональных методов исследования, ультразвуковой диагностики и восстановительной терапии.

400138, Волгоград, ул. имени Землячки, д. 76, корп. 2

Ninel A. Aleksandrova - Cand. Sci. (Med.), Senior Researcher of the Laboratory of Functional Diagnostic Methods, Ultrasound Diagnostics, and Rehabilitation Therapy.

76, Bldg. 2, Zemlyachka St., Volgograd, 400138

nynel68@mail.ruhttps://orcid.org/0000-0002-8864-9570ЗаводовскийБ. В.ZavodovskyB. V.

Заводовский Борис Валерьевич - д.м.н., профессор, заведующий лабораторией методов лечения и профилактики заболеваний суставов.

400138, Волгоград, ул. имени Землячки, д. 76, корп. 2

Boris V. Zavodovsky - Dr. Sci. (Med.), Professor, Head of the Laboratory of Methods for the Treatment and Prevention of Joint Diseases.

76, Bldg. 2, Zemlyachka St., Volgograd, 400138

pebma@mail.ruНаучно-исследовательский институт клинической и экспериментальной ревматологии имени А.Б. ЗборовскогоРоссияResearch Institute of Clinical and Experimental Rheumatology named after A.B. ZborovskyRussian Federation202614092026012173181Copyright © Сивордова Л.Е., Папичев Е.В., Полякова Ю.В., Ахвердян Ю.Р., Александрова Н.А., Заводовский Б.В., 20262026Сивордова Л.Е., Папичев Е.В., Полякова Ю.В., Ахвердян Ю.Р., Александрова Н.А., Заводовский Б.В.Sivordova L.E., Papichev E.V., Polyakova Y.V., Akhverdyan Y.R., Aleksandrova N.A., Zavodovsky B.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/10414

Моноцитарный хемотаксический (хемоаттрактивный) протеин-1 (MCP-1), также известный как C-C motif chemokine ligand 2 (CCL2), играет важную роль в регуляции воспалительных процессов при различных патологиях. Прямо или косвенно он участвует в патогенезе онкологических и легочных патологий, нейровоспалительных, сердечно-сосудистых и кожных заболеваний. Доказана роль MCP-1 в качестве биомаркера тяжести течения этих болезней. Значение данного хемокина в патогенезе имунновоспалительных ревматических заболеваний на сегодняшний день изучено недостаточно и представляет большой научный интерес. Целью данного литературного обзора являлся анализ научных данных о патогенетической роли МСР-1 при ревматоидном артрите (РА), а также оценка перспектив его использования в клинической практике. Поиск научных публикаций был проведен в электронных базах данных PubMed, Google Scholar и eLIBRARY.RU. В анализ были включены публикации на русском и английском языках, опубликованные до февраля 2026 г. Представленный обзор научной литературы позволил уточнить роль MCP-1 в патогенезе РА и осветить одно из наиболее актуальных направлений научных исследований – разработку новых лекарственных препаратов (антагонистов рецептора данного хемокина – CCR2). Показано, что MCP-1 играет ключевую роль в усилении воспалительного каскада и тесно связан с хроническим неконтролируемым воспалением. Свое биологическое воздействие на миграцию, инфильтрацию и дифференцировку иммунных клеток MCP-1 оказывает путем связывания со своим рецептором CCR2. Ось MCP-1 (CCL2)/CCR2 является центральным воспалительным механизмом, привлекающим моноциты к очагу воспаления. На современном этапе предложенные лекарственные молекулы антагонистов CCR2 недостаточно эффективны, а экстраполяция результатов экспериментов на животных моделях не оправдывает себя в клинических исследованиях. Тем не менее в перспективе разработка новых антагонистов CCR2 и/или их комбинации с другими иммуномодуляторами может быть многообещающей стратегией повышения эффективности лечения РА.

Monocyte chemotactic protein-1 (MCP-1), also known as C-C motif chemokine ligand 2 (CCL2), plays a key role in regulating inflammation in various pathologies. It is directly or indirectly implicated in the pathogenesis of oncologic and pulmonary diseases, neuroinflammatory, cardiovascular, and skin diseases. Its role as a biomarker of disease severity has been proven. The role of this chemokine in the pathogenesis of immune-mediated inflammatory rheumatic diseases remains insufficiently studied and is of considerable scientific interest. The aim of this literature review was to analyze scientific data on the pathogenetic role of MCP-1 in rheumatoid arthritis (RA) and the prospects for its use in clinical practice. A search for scientific publications was performed in the electronic databases PubMed, Google Scholar, and eLIBRARY.RU, published in Russian and English before February 2026. This review of the scientific literature clarified the role of MCP-1 in the pathogenesis of RA and highlighted one of the most pressing areas of scientific research: the development of new drugs (antagonists of the receptor of this chemokine, CCR2). MCP-1 has been shown to play a key role in enhancing the inflammatory cascade and is closely associated with chronic, uncontrolled inflammation. MCP-1 exerts its biological effects on migration, infiltration, and differentiation of immune cells by binding to its receptor, CCR2. The MCP-1 (CCL2)/CCR2 axis is a central inflammatory mechanism that attracts monocytes to the site of inflammation. Currently, proposed CCR2 antagonist drugs are not sufficiently effective, and extrapolation of experimental results in animal models does not justify clinical trials. Nevertheless, the development of new CCR2 antagonists and/or their combination with other immunomodulators may be a promising strategy for improving the effectiveness of RA treatment.

иммуновоспалительные заболеванияревматоидный артритхемотаксисцитокиныхемокиныхемотаксический (хемоаттрактивный) протеин-1МСР-1C-C хемокиновый лиганд 2CCL2CCR2immune-inflammatory diseasesrheumatoid arthritischemotaxiscytokineschemokineschemotactic protein-1MCP-1C-C chemokine ligand 2CCL2CCR2ReferencesLaurindo LF, de Maio MC, Barbalho SM, Guiguer EL, Araújo AC, de Alvares Goulart R et al. Organokines in Rheumatoid Arthritis: A Critical Review. Int J Mol Sci. 2022;23(11):6193. https://doi.org/10.3390/ijms23116193.Laurindo LF, de Maio MC, Barbalho SM, Guiguer EL, Araújo AC, de Alvares Goulart R et al. Organokines in Rheumatoid Arthritis: A Critical Review. Int J Mol Sci. 2022;23(11):6193. https://doi.org/10.3390/ijms23116193.Aleksandrova NV, Aleksandrov VA, Zagorodneva EA, Nikitina NV, Aleksandrov AV. Cytokines as potential biomarkers of atherosclerotic vascular lesions in rheumatoid arthritis. Aging Clin Exp Res. 2023;35:395–396. https://doi.org/10.1007/s40520-023-02442-7.Aleksandrova NV, Aleksandrov VA, Zagorodneva EA, Nikitina NV, Aleksandrov AV. Cytokines as potential biomarkers of atherosclerotic vascular lesions in rheumatoid arthritis. Aging Clin Exp Res. 2023;35:395–396. https://doi.org/10.1007/s40520-023-02442-7.Papichev EV, Sivordova LE, Akhverdyan YuR, Polyakova YuV, Zavodovsky BV. AFABP in patients with rheumatoid arthritis. Aging Clin Exp Res. 2025;37:272. https://doi.org/10.1007/s40520-025-03119-z.Papichev EV, Sivordova LE, Akhverdyan YuR, Polyakova YuV, Zavodovsky BV. AFABP in patients with rheumatoid arthritis. Aging Clin Exp Res. 2025;37:272. https://doi.org/10.1007/s40520-025-03119-z.Han QF, Wu MQ, Zhu ML, Liu YX, Yang X, Zhang WQ. Skin-Soothing Properties of Juniperus formosana Hayata Revealed by Bioactivity-Based Molecular Networking. Chem Biodivers. 2026;23(2):e00498. https://doi.org/10.1002/cbdv.202500498.Han QF, Wu MQ, Zhu ML, Liu YX, Yang X, Zhang WQ. Skin-Soothing Properties of Juniperus formosana Hayata Revealed by Bioactivity-Based Molecular Networking. Chem Biodivers. 2026;23(2):e00498. https://doi.org/10.1002/cbdv.202500498.Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12(2):121–127. https://doi.org/10.1016/s10747613(00)80165-x.Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12(2):121–127. https://doi.org/10.1016/s10747613(00)80165-x.Singh S, Anshita D, Ravichandiran V. MCP-1: Function, regulation, and involvement in disease. Int Immunopharmacol. 2021;101(Pt B):107598. https://doi.org/10.1016/j.intimp.2021.107598.Singh S, Anshita D, Ravichandiran V. MCP-1: Function, regulation, and involvement in disease. Int Immunopharmacol. 2021;101(Pt B):107598. https://doi.org/10.1016/j.intimp.2021.107598.Van Coillie E, Van Damme J, Opdenakker G. The MCP/eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev. 1999;10(1):61–86. https://doi.org/10.1016/s1359-6101(99)00005-2.Van Coillie E, Van Damme J, Opdenakker G. The MCP/eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev. 1999;10(1):61–86. https://doi.org/10.1016/s1359-6101(99)00005-2.Yoshimura T, Yuhki N, Moore SK, Appella E, Lerman MI, Leonard EJ. Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE. FEBS Lett. 1989;244(2):487–493. https://doi.org/10.1016/0014-5793(89)80590-3.Yoshimura T, Yuhki N, Moore SK, Appella E, Lerman MI, Leonard EJ. Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE. FEBS Lett. 1989;244(2):487–493. https://doi.org/10.1016/0014-5793(89)80590-3.Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29(6):313–326. https://doi.org/10.1089/jir.2008.0027.Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29(6):313–326. https://doi.org/10.1089/jir.2008.0027.Lin J, Kakkar V, Lu X. Impact of MCP-1 in atherosclerosis. Curr Pharm Des. 2014;20(28):4580–4588. https://doi.org/10.2174/1381612820666140522115801.Lin J, Kakkar V, Lu X. Impact of MCP-1 in atherosclerosis. Curr Pharm Des. 2014;20(28):4580–4588. https://doi.org/10.2174/1381612820666140522115801.Burley SK, Bhikadiya C, Bi C, Bittrich S, Chao H, Chen L et al. RCSB Protein Data Bank (RCSB.org): delivery of experimentally-determined PDB structures alongside one million computed structure models of proteins from artificial intelligence/machine learning. Nucleic Acids Res. 2023;51(D1):D488–D508. https://doi.org/10.1093/nar/gkac1077.Burley SK, Bhikadiya C, Bi C, Bittrich S, Chao H, Chen L et al. RCSB Protein Data Bank (RCSB.org): delivery of experimentally-determined PDB structures alongside one million computed structure models of proteins from artificial intelligence/machine learning. Nucleic Acids Res. 2023;51(D1):D488–D508. https://doi.org/10.1093/nar/gkac1077.Schmid R, Heuckeroth S, Korf A, Smirnov A, Myers O, Dyrlund TS et al. Integrative analysis of multimodal mass spectrometry data in MZmine 3. Nat Biotechnol. 2023;41(4):447–449. https://doi.org/10.1038/s41587-023-01690-2.Schmid R, Heuckeroth S, Korf A, Smirnov A, Myers O, Dyrlund TS et al. Integrative analysis of multimodal mass spectrometry data in MZmine 3. Nat Biotechnol. 2023;41(4):447–449. https://doi.org/10.1038/s41587-023-01690-2.Monteclaro FS, Charo IF. The amino-terminal domain of CCR2 is both necessary and sufficient for high affinity binding of monocyte chemoattractant protein 1. Receptor activation by a pseudo-tethered ligand. J Biol Chem. 1997;272(37):23186–23190. https://doi.org/10.1074/jbc.272.37.23186.Monteclaro FS, Charo IF. The amino-terminal domain of CCR2 is both necessary and sufficient for high affinity binding of monocyte chemoattractant protein 1. Receptor activation by a pseudo-tethered ligand. J Biol Chem. 1997;272(37):23186–23190. https://doi.org/10.1074/jbc.272.37.23186.Zhu S, Liu M, Bennett S, Wang Z, Pfleger KDG, Xu J. The molecular structure and role of CCL2 (MCP-1) and C-C chemokine receptor CCR2 in skeletal biology and diseases. J Cell Physiol. 2021;236(10):7211–7222. https://doi.org/10.1002/jcp.30375.Zhu S, Liu M, Bennett S, Wang Z, Pfleger KDG, Xu J. The molecular structure and role of CCL2 (MCP-1) and C-C chemokine receptor CCR2 in skeletal biology and diseases. J Cell Physiol. 2021;236(10):7211–7222. https://doi.org/10.1002/jcp.30375.Harigai M, Hara M, Yoshimura Т, Leonard EJ, Inoue K, Kashiwazaki S. Monocyte chemoattractant protein-1 (MCP-1) in inflammatory joint diseases and its involvement in the cytokine network of rheumatoid synovium. Clin Immunol Immunopathol. 1993;69(1):83–91. https://doi.org/10.1006/clin.1993.1153.Harigai M, Hara M, Yoshimura Т, Leonard EJ, Inoue K, Kashiwazaki S. Monocyte chemoattractant protein-1 (MCP-1) in inflammatory joint diseases and its involvement in the cytokine network of rheumatoid synovium. Clin Immunol Immunopathol. 1993;69(1):83–91. https://doi.org/10.1006/clin.1993.1153.Bogatyreva AI, Gerasimova EV, Kirichenko TV, Markina YuV, Popkova TV, Shalygina MV et al. Proinflammatory Activation of Monocytes in Patients with Immunoinflammatory Rheumatic Diseases. Dokl. Biochem. Biophys. 2024;517(1):228–234. https://doi.org/10.1134/S1607672924700959.Bogatyreva AI, Gerasimova EV, Kirichenko TV, Markina YuV, Popkova TV, Shalygina MV et al. Proinflammatory Activation of Monocytes in Patients with Immunoinflammatory Rheumatic Diseases. Dokl. Biochem. Biophys. 2024;517(1):228–234. https://doi.org/10.1134/S1607672924700959.Caso F, Saviano A, Tasso M, Raucci F, Marigliano N, Passavanti S et al. Analysis of rheumatoidvs psoriatic arthritis synovial fluid reveals differential macrophage (CCR2) and T helper subsets (STAT3/4 and FOXP3) activation. Autoimmun Rev. 2022;21(12):103207. https://doi.org/10.1016/j.autrev.2022.103207.Caso F, Saviano A, Tasso M, Raucci F, Marigliano N, Passavanti S et al. Analysis of rheumatoidvs psoriatic arthritis synovial fluid reveals differential macrophage (CCR2) and T helper subsets (STAT3/4 and FOXP3) activation. Autoimmun Rev. 2022;21(12):103207. https://doi.org/10.1016/j.autrev.2022.103207.Korzeniowska A, Daca A, Szarecka M, Bykowska M, Witkowski J, Bryl E. Differences in Salivary Cytokinome and Pathogen Load Between Rheumatoid Arthritis and Other Rheumatic Disease Patients. Int J Mol Sci. 2024;26(1):197. https://doi.org/10.3390/ijms26010197.Korzeniowska A, Daca A, Szarecka M, Bykowska M, Witkowski J, Bryl E. Differences in Salivary Cytokinome and Pathogen Load Between Rheumatoid Arthritis and Other Rheumatic Disease Patients. Int J Mol Sci. 2024;26(1):197. https://doi.org/10.3390/ijms26010197.Bestard-Escalas J, Sasportes O, Ameraoui H, González-Nicolau M, Alhouayek M, Muccioli GG. The endocannabinoid-derived prostaglandin glycerol esters and prostaglandin ethanolamides modulate intestinal epithelial hallmarks of colitis. Biochim Biophys Acta Mol Cell Biol Lipids. 2026;1871(2):159719. https://doi.org/10.1016/j.bbalip.2026.159719.Bestard-Escalas J, Sasportes O, Ameraoui H, González-Nicolau M, Alhouayek M, Muccioli GG. The endocannabinoid-derived prostaglandin glycerol esters and prostaglandin ethanolamides modulate intestinal epithelial hallmarks of colitis. Biochim Biophys Acta Mol Cell Biol Lipids. 2026;1871(2):159719. https://doi.org/10.1016/j.bbalip.2026.159719.Bai Z, Yang S, Ren J, Zhang C, Chen X, Huang H et al. Exploring the differential functions of circulating follicular helper T and peripheral helper T cells in rheumatoid arthritis based on metabolism patterns. Front Immunol. 2025;16:1608675. https://doi.org/10.3389/fimmu.2025.1608675.Bai Z, Yang S, Ren J, Zhang C, Chen X, Huang H et al. Exploring the differential functions of circulating follicular helper T and peripheral helper T cells in rheumatoid arthritis based on metabolism patterns. Front Immunol. 2025;16:1608675. https://doi.org/10.3389/fimmu.2025.1608675.Chen W, Fang Y, Wang H, Tan X, Zhu X, Xu Z et al. Role of chemokine receptor 2 in rheumatoid arthritis: A research update. Int Immunopharmacol. 2023;116:109755. https://doi.org/10.1016/j.intimp.2023.109755.Chen W, Fang Y, Wang H, Tan X, Zhu X, Xu Z et al. Role of chemokine receptor 2 in rheumatoid arthritis: A research update. Int Immunopharmacol. 2023;116:109755. https://doi.org/10.1016/j.intimp.2023.109755.Quinones MP, Ahuja SK, Jimenez F, Schaefer J, Garavito E, Rao A et al. Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis. J Clin Invest. 2004;113(6):856–866. https://doi.org/10.1172/JCI20126.Quinones MP, Ahuja SK, Jimenez F, Schaefer J, Garavito E, Rao A et al. Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis. J Clin Invest. 2004;113(6):856–866. https://doi.org/10.1172/JCI20126.Rampersad RR, Tarrant TK, Vallanat CT, Quintero-Matthews T, Weeks MF, Esserman DA et al. Enhanced Th17-cell responses render CCR2-deficient mice more susceptible for autoimmune arthritis. PLoS ONE. 2011;6(10):e25833. https://doi.org/10.1371/journal.pone.0025833.Rampersad RR, Tarrant TK, Vallanat CT, Quintero-Matthews T, Weeks MF, Esserman DA et al. Enhanced Th17-cell responses render CCR2-deficient mice more susceptible for autoimmune arthritis. PLoS ONE. 2011;6(10):e25833. https://doi.org/10.1371/journal.pone.0025833.Liou LB, Fang YF, Tsai PH, Chen YF, Chang CT, Chen CC, Chiang WY. Immunoregulatory Cells and Cytokines Discriminate Disease Activity Score 28-Remission Statuses and Ultrasound Grades in Rheumatoid Arthritis Patients with Non-High Disease Activity. Int J Mol Sci. 2024;25(16):8694. https://doi.org/10.3390/ijms25168694.Liou LB, Fang YF, Tsai PH, Chen YF, Chang CT, Chen CC, Chiang WY. Immunoregulatory Cells and Cytokines Discriminate Disease Activity Score 28-Remission Statuses and Ultrasound Grades in Rheumatoid Arthritis Patients with Non-High Disease Activity. Int J Mol Sci. 2024;25(16):8694. https://doi.org/10.3390/ijms25168694.Liou LB, Tsai PH, Fang YF, Chen YF, Chang CT, Chen CC, Chiang WY. B-Cell ST6Gal1/Neuraminidase 1 Ratios Inversely Predict the Combined Remission and Low-Disease-Activity Subgroup with DAS28-MCP-1 and SDAI Scores for Rheumatoid Arthritis. Int J Mol Sci. 2025;26(17):8226. https://doi.org/10.3390/ijms26178226.Liou LB, Tsai PH, Fang YF, Chen YF, Chang CT, Chen CC, Chiang WY. B-Cell ST6Gal1/Neuraminidase 1 Ratios Inversely Predict the Combined Remission and Low-Disease-Activity Subgroup with DAS28-MCP-1 and SDAI Scores for Rheumatoid Arthritis. Int J Mol Sci. 2025;26(17):8226. https://doi.org/10.3390/ijms26178226.Tong X, Yu D, Yu L, Chen W, Wen Y, Gu P. Exploring the role of monocyte chemoattractant protein-1 in fibroblast-like synovial cells in rheumatoid arthritis. PeerJ. 2021;9:e11973. https://doi.org/10.7717/peerj.11973.Tong X, Yu D, Yu L, Chen W, Wen Y, Gu P. Exploring the role of monocyte chemoattractant protein-1 in fibroblast-like synovial cells in rheumatoid arthritis. PeerJ. 2021;9:e11973. https://doi.org/10.7717/peerj.11973.Tsai PH, Liou LB. Effective Assessment of Rheumatoid Arthritis Disease Activity and Outcomes Using Monocyte Chemotactic Protein-1 (MCP-1) and Disease Activity Score 28-MCP-1. Int J Mol Sci. 2024;25(21):11374. https://doi.org/10.3390/ijms252111374.Tsai PH, Liou LB. Effective Assessment of Rheumatoid Arthritis Disease Activity and Outcomes Using Monocyte Chemotactic Protein-1 (MCP-1) and Disease Activity Score 28-MCP-1. Int J Mol Sci. 2024;25(21):11374. https://doi.org/10.3390/ijms252111374.Ellingsen T, Hornung N, Møller BK, Poulsen JH, Stengaard-Pedersen K. Differential effect of methotrexate on the increased CCR2 density on circulating CD4 T lymphocytes and monocytes in active chronic rheumatoid arthritis, with a down regulation only on monocytes in responders. Ann Rheum Dis. 2007;66(2):151–157. https://doi.org/10.1136/ard.2006.054056.Ellingsen T, Hornung N, Møller BK, Poulsen JH, Stengaard-Pedersen K. Differential effect of methotrexate on the increased CCR2 density on circulating CD4 T lymphocytes and monocytes in active chronic rheumatoid arthritis, with a down regulation only on monocytes in responders. Ann Rheum Dis. 2007;66(2):151–157. https://doi.org/10.1136/ard.2006.054056.Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis. 2015;74(6):1311–1316. https://doi.org/10.1136/annrheumdis-2014-206028.Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis. 2015;74(6):1311–1316. https://doi.org/10.1136/annrheumdis-2014-206028.Aeberli D, Kamgang R, Balani D, Hofstetter W, Villiger PM, Seitz M. Regulation of peripheral classical and non-classical monocytes on infliximab treatment in patients with rheumatoid arthritis and ankylosing spondylitis. RMD Open. 2016;2(1):e000079. https://doi.org/10.1136/rmdopen-2015-000079.Aeberli D, Kamgang R, Balani D, Hofstetter W, Villiger PM, Seitz M. Regulation of peripheral classical and non-classical monocytes on infliximab treatment in patients with rheumatoid arthritis and ankylosing spondylitis. RMD Open. 2016;2(1):e000079. https://doi.org/10.1136/rmdopen-2015-000079.Бобкова АО, Лила АМ, Каратеев АЕ. Предикторы неэффективности терапии у пациентов с ревматоидным артритом, нуждающихся в смене ГИБП/иJAK: данные одноцентрового проспективного исследования. Терапевтический архив. 2025;97(12):973–980. https://doi.org/10.26442/00403660.2025.12.203452.Bobkova AO, Lila AM, Karateev AE. Predictors of ineffective therapy in patients with rheumatoid arthritis requiring bDMARDs/JAKi switching: data from a single-center prospective study. Terapevticheskii Arkhiv. 2026;97(12):973–980. (In Russ.) https://doi.org/10.26442/00403660.2025.12.203452.Anno S, Okano T, Mamoto K, Yamada Y, Mandai K, Orita K et al. Efficacy and safety of Janus kinase inhibitors in patients with difficult-to-treat rheumatoid arthritis. Mod Rheumatol. 2025;35(2):225–233. https://doi.org/10.1093/mr/roae077.Anno S, Okano T, Mamoto K, Yamada Y, Mandai K, Orita K et al. Efficacy and safety of Janus kinase inhibitors in patients with difficult-to-treat rheumatoid arthritis. Mod Rheumatol. 2025;35(2):225–233. https://doi.org/10.1093/mr/roae077.Заводовский БВ, Сивордова ЛЕ, Полякова ЮВ, Ахвердян ЮР, Папичев ЕВ. Оценка безопасности, переносимости и эффективностипервого отечественного генерика ацеклофенака у пациентов с недифференцированным артритом. Терапевтический архив. 2020;92(5):61–68. https://doi.org/10.26442/00403660.2020.05.000589.Zavodovsky BV, Sivordova LE, Polyakova YuV, Akhverdyan YuR, Papichev EV. Assessment of the safety, tolerability and effectiveness of first Russian generic aceclofenac in patients with undifferentiated peripheral inflammatory arthritis. Terapevticheskii Arkhiv. 2020;92(5):61–68. (In Russ.) https://doi.org/10.26442/00403660.2020.05.000589.Rafei M, Berchiche YA, Birman E, Boivin MN, Young YK, Wu JH et al. An engineered GM-CSF-CCL2 fusokine is a potent inhibitor of CCR2-driven inflammation as demonstrated in a murine model of inflammatory arthritis. J Immunol. 2009;183(3):1759–1766. https://doi.org/10.4049/jimmunol.0900523.Rafei M, Berchiche YA, Birman E, Boivin MN, Young YK, Wu JH et al. An engineered GM-CSF-CCL2 fusokine is a potent inhibitor of CCR2-driven inflammation as demonstrated in a murine model of inflammatory arthritis. J Immunol. 2009;183(3):1759–1766. https://doi.org/10.4049/jimmunol.0900523.Laborde E, Macsata RW, Meng F, Peterson BT, Robinson L, Schow SR et al. Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function. J Med Chem. 2011;54(6):1667–1681. https://doi.org/10.1021/jm1012903.Laborde E, Macsata RW, Meng F, Peterson BT, Robinson L, Schow SR et al. Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function. J Med Chem. 2011;54(6):1667–1681. https://doi.org/10.1021/jm1012903.Flegar D, Filipović M, Šućur A, Markotić A, Lukač N, Šisl D et al. Preventive CCL2/CCR2 Axis Blockade Suppresses Osteoclast Activity in a Mouse Model of Rheumatoid Arthritis by Reducing Homing of CCR2hi Osteoclast Progenitors to the Affected Bone. Front Immunol. 2021;12:767231. https://doi.org/10.3389/fimmu.2021.767231.Flegar D, Filipović M, Šućur A, Markotić A, Lukač N, Šisl D et al. Preventive CCL2/CCR2 Axis Blockade Suppresses Osteoclast Activity in a Mouse Model of Rheumatoid Arthritis by Reducing Homing of CCR2hi Osteoclast Progenitors to the Affected Bone. Front Immunol. 2021;12:767231. https://doi.org/10.3389/fimmu.2021.767231.Fang Z, He D, Yu B, Liu F, Zuo J, Li Y et al. High-Throughput Study of the Effects of Celastrol on Activated Fibroblast-Like Synoviocytes from Patients with Rheumatoid Arthritis. Genes. 2017;8(9):221. https://doi.org/10.3390/genes8090221.Fang Z, He D, Yu B, Liu F, Zuo J, Li Y et al. High-Throughput Study of the Effects of Celastrol on Activated Fibroblast-Like Synoviocytes from Patients with Rheumatoid Arthritis. Genes. 2017;8(9):221. https://doi.org/10.3390/genes8090221.Aslani M, Ahmadzadeh A, Aghazadeh Z, Zaki-Dizaji M, Sharifi L, Hosseini M, Mirshafiey A. Influence of β-D-mannuronic Acid, as a New Member of Non-steroidal AntiInflammatory Drugs Family, on the Expression Pattern of Chemokines and their Receptors in Rheumatoid Arthritis. Curr Drug Discov Technol. 2021;18(1):65–74. https://doi.org/10.2174/1570163816666191023103118.Aslani M, Ahmadzadeh A, Aghazadeh Z, Zaki-Dizaji M, Sharifi L, Hosseini M, Mirshafiey A. Influence of β-D-mannuronic Acid, as a New Member of Non-steroidal AntiInflammatory Drugs Family, on the Expression Pattern of Chemokines and their Receptors in Rheumatoid Arthritis. Curr Drug Discov Technol. 2021;18(1):65–74. https://doi.org/10.2174/1570163816666191023103118.Nielsen MA, Køster D, Mehta AY, Stengaard-Pedersen K, Busson P, Junker P et al. Increased Galectin-9 Levels Correlate with Disease Activity in Patients with DMARD-Naïve Rheumatoid Arthritis and Modulate the Secretion of MCP-1 and IL-6 from Synovial Fibroblasts. Cells. 2023;12(2):327. https://doi.org/10.3390/cells12020327.Nielsen MA, Køster D, Mehta AY, Stengaard-Pedersen K, Busson P, Junker P et al. Increased Galectin-9 Levels Correlate with Disease Activity in Patients with DMARD-Naïve Rheumatoid Arthritis and Modulate the Secretion of MCP-1 and IL-6 from Synovial Fibroblasts. Cells. 2023;12(2):327. https://doi.org/10.3390/cells12020327.Kazemi-Lomedasht F, Eftekhari Z, Chiani M, Ramezanpour S, Montazeri A. Ameliorative effects of chitosan nanoparticles containing a scorpion-derived potassium channel inhibitory peptide (alpha-KTx 3.13) in a juvenile model of rheumatoid arthritis. Int Immunopharmacol. 2026;168(Pt 2):115817. https://doi.org/10.1016/j.intimp.2025.115817.Kazemi-Lomedasht F, Eftekhari Z, Chiani M, Ramezanpour S, Montazeri A. Ameliorative effects of chitosan nanoparticles containing a scorpion-derived potassium channel inhibitory peptide (alpha-KTx 3.13) in a juvenile model of rheumatoid arthritis. Int Immunopharmacol. 2026;168(Pt 2):115817. https://doi.org/10.1016/j.intimp.2025.115817.Pan T, Chen SY, Kung CW, Chen HY, Cheng PY, Shen HH et al. Coenzyme Q10 ameliorates obesity by promoting white adipose tissue browning and preserving mitochondrial dynamics in ovariectomized rats fed a high-fat diet. J Nutr Biochem. 2026;149:110187. https://doi.org/10.1016/j.jnutbio.2025.110187.Pan T, Chen SY, Kung CW, Chen HY, Cheng PY, Shen HH et al. Coenzyme Q10 ameliorates obesity by promoting white adipose tissue browning and preserving mitochondrial dynamics in ovariectomized rats fed a high-fat diet. J Nutr Biochem. 2026;149:110187. https://doi.org/10.1016/j.jnutbio.2025.110187.Ziaastani Z, Kalantari-Khandani B, Niazi MJ, Kazemipour A. Identification of critical genes and metabolic pathways in rheumatoid arthritis and osteoporosis toward drug repurposing. Comput Biol Med. 2024;180:108912. https://doi.org/10.1016/j.compbiomed.2024.108912.Ziaastani Z, Kalantari-Khandani B, Niazi MJ, Kazemipour A. Identification of critical genes and metabolic pathways in rheumatoid arthritis and osteoporosis toward drug repurposing. Comput Biol Med. 2024;180:108912. https://doi.org/10.1016/j.compbiomed.2024.108912.Gao W, Gao Z, Chen Y, Wang Y, Li Y, Qian Y et al. Targeting chemokine signaling networks for therapeutics in skeletal disorders. Front Endocrinol. 2025;16:1667440. https://doi.org/10.3389/fendo.2025.1667440.Gao W, Gao Z, Chen Y, Wang Y, Li Y, Qian Y et al. Targeting chemokine signaling networks for therapeutics in skeletal disorders. Front Endocrinol. 2025;16:1667440. https://doi.org/10.3389/fendo.2025.1667440.

The authors declare that there are no conflicts of interest present.